Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer.

Tan, Tingfei; Han, Gongwei; Cheng, Ziwei; Jiang, Jiemei; Zhang, Li; Xia, Zitong; Wang, Xinmeng; Xia, Quan

Tan, Tingfei; Han, Gongwei; Cheng, Ziwei; Jiang, Jiemei; Zhang, Li; Xia, Zitong; Wang, Xinmeng; Xia, Quan.

Afiliación

Tan T; Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Han G; School of Pharmacy, Anhui Medical University, Hefei, China.
Cheng Z; School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.
Jiang J; Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Zhang L; Department of Pharmacy, The Second Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Xia Z; School of Pharmacy, Anhui Medical University, Hefei, China.
Wang X; Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Xia Q; Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Front Pharmacol ; 13: 918219, 2022.

Article en En | MEDLINE | ID: mdl-35814206

Palabras clave

CYP450 gene polymorphisms; adverse reactions; anlotinib; lung cancer; plasma concentration

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google